pharma · Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer · Acute Myeloid Leukemia
Stemline Therapeutics (United
Stemline Therapeutics B.V.
Stemline Therapeutics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer, Acute Myeloid Leukemia, Advanced
Company details
- Status
- Public
- HQ
- New York, USA
- Employees
- 767
- Programs
- 7
- Drugs
- 29
- Patents
- 0
STML-ELA-0422
Phase 3 · small molecule · Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
STML-ELA-0422 for Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence is a Phase 3 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Internal code STML-ELA-0422
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Stemline Therapeutics B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
- Status
- active
- Trials
- 1